The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...
By speeding lifesaving drugs’ way to market and focusing on the underlying causes of disease, the pathway has helped save ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval of a treatment for adults with metastatic ...
Shares of DBV Technologies were trading higher on the Nasdaq after hours Wednesday, following the company confirming alignment with the Food and Drug Administration on an accelerated approval for its ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY ALS ...
Gene therapy company uniQure N.V. (QURE) announced Tuesday that the company reached agreement with the U.S. Food and Drug ...
The draft guidance provides information on the agency’s accelerated approval process and criteria for approval.
Cellectar Biosciences is laying off 60% of its employees and halting work on its sole clinical-stage radiotherapy after the ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...